JORGE CASTILLO to B-Lymphocytes
This is a "connection" page, showing publications JORGE CASTILLO has written about B-Lymphocytes.
Connection Strength
2.327
-
Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324.
Score: 0.414
-
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
Score: 0.405
-
CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8(3):343-54.
Score: 0.380
-
The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30.
Score: 0.380
-
Waldenstr?m macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
Score: 0.367
-
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
Score: 0.102
-
Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
Score: 0.094
-
Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leuk Lymphoma. 2013 Aug; 54(8):1647-51.
Score: 0.082
-
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar; 21(3):355-61.
Score: 0.077
-
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
Score: 0.026